Publication:
The Quazar AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of Oral CC-486 in Patients with Acute Myeloid Leukemia (AML) in First Remission

Simple item page
dc.authorwosidDöhner, Hartmut/C-8933-2016
dc.authorwosidMontesinos, Pau/Gyu-2673-2022
dc.authorwosidCakar, Merih/Gya-1392-2022
dc.authorwosidWei, Andrew/F-3707-2012
dc.authorwosidRavandi, Farhad/Goh-3538-2022
dc.authorwosidPorkka, Kimmo/O-2323-2016
dc.authorwosidPfeilstöcker, Michael/Aan-6206-2021
dc.contributor.authorDoehner, H.
dc.contributor.authorWei, A. H.
dc.contributor.authorPocock, C.
dc.contributor.authorMontesinos, P.
dc.contributor.authorDombret, H.
dc.contributor.authorRavandi, F.
dc.contributor.authorRoboz, G. J.
dc.date.accessioned2025-12-11T00:50:14Z
dc.date.issued2020
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Doehner, H.] Ulm Univ Hosp, Dept Internal Med 3, Ulm, Germany; [Wei, A. H.] Alfred Hosp, Melbourne, Vic, Australia; [Wei, A. H.] Monash Univ, Melbourne, Vic, Australia; [Pocock, C.] Kent & Canterbury Hosp, Canterbury, Kent, England; [Montesinos, P.] Inst Carlos III, CIBERONC, Madrid, Spain; [Montesinos, P.] Hosp Univ & Politecn La Fe, Valenica, Spain; [Dombret, H.] Hop St Louis, AP HP, Paris, France; [Dombret, H.] Univ Paris, Inst Rech St Louis, Paris, France; [Ravandi, F.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Sayar, H.] Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA; [Jang, J. H.] Samsung Med Ctr, Seoul, South Korea; [Porkka, K.] Univ Helsinki, HUS Comprehens Canc Ctr, Hematol Res Unit Helsinki, Helsinki, Finland; [Porkka, K.] Univ Helsinki, ICAN Digital Precis Canc Med Flagship, Helsinki, Finland; [Selleslag, D.] AZ Sint Jan Brugge Oostende AV, Brugge, Belgium; [Sandhu, I.] Univ Hosp, Edmonton, AB, Canada; [Turgut, M.] Ondokuz Mayis Univ, Samsun, Turkey; [Giai, V.] Antonio & Biagio & Cesare Arrigo Hosp, Alessandria, Italy; [Ofran, Y.] Rambam Med Ctr, Haifa, Israel; [Ofran, Y.] Technion, Fac Med, Haifa, Israel; [Cakar, M. K.] Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Ankara, Turkey; [Botelho de Sousa, A.] Hosp Capuchos CHLC, Lisbon, Portugal; [Rybka, J.] Wroclaw Med Univ, Wroclaw, Poland; [Frairia, C.] Citta Salute Sci, Turin, Italy; [Borin, L.] Osped San Gerardo, Monza, Italy; [Beltrami, G.] Osped Policlin San Martino, Genoa, Italy; [Cermak, J.] Ustav Hematol Krevni Transfuze, Prague, Czech Republic; [Pfeilstoecker, M.] Hanusch Hosp, Vienna, Austria; [Thol, F.] Hannover Med Sch, Hannover, Germany; [Feldmann, G.] Univ Hosp Bonn, Bonn, Germany; [Ossenkoppele, G. J.] Vrije Univ Amsterdam Med Ctr, Amsterdam UMC, Amsterdam, Netherlands; [La Torre, I.] Celgene, Boudry, Switzerland; [Skikne, B.; Kumar, K.; Dong, Q.; Beach, C. L.] Bristol Myers Squibb Co, Princeton, NJ USA; [Skikne, B.] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA; [Roboz, G. J.] Weill Cornell Med, New York, NY USA; [Roboz, G. J.] New York Presbyterian Hosp, New York, NY USAen_US
dc.description.sponsorshipAbbvie; Agios; Amgen; Astellas; Astex; Celgene; Janssen; Jazz; Helsinn; Novartis; Oxford Biochemicals; Roche; Actinium; Amphivena; Argenx; Array Biopharma; AstraZeneca; Bayer; Celltrion; Daiichi Sankyo; Eisai; Epizyme; Jasper Therapeutics; MEI Pharma; Orsenix; Otsuka; Pfizer; Roche/Genentech; Sandoz; Takeda; Trovageneen_US
dc.description.sponsorshipHartmut Dohner: Financing of Scientific Research: Abbvie, Agios, Amgen, Astellas, Astex, Celgene, Janssen, Jazz, Helsinn, Novartis, Oxford Biochemicals, Roche,; Expert Testimony: Amgen, BMS, Celgene, Jazz, Novartis, Pfizer, Sunesis, Gail J. Roboz: Financing of Scientific Research: AbbVie, Actinium, Agios, Amphivena, Argenx, Array Biopharma, Astex, Astellas, AstraZeneca, Bayer, Celgene, Celltrion, Daiichi Sankyo, Eisai, Epizyme, Helsinn, Janssen, Jasper Therapeutics, Jazz, MEI Pharma, Novartis, Orsenix, Otsuka, Pfizer, Roche/Genentech, Sandoz, Takeda, Trovagene; Expert Testimony: Cellectisen_US
dc.description.woscitationindexScience Citation Index Expanded
dc.identifier.endpage38en_US
dc.identifier.issn2296-5270
dc.identifier.issn2296-5262
dc.identifier.scopusqualityQ3
dc.identifier.startpage38en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12712/39608
dc.identifier.volume43en_US
dc.identifier.wosWOS:000575955000106
dc.identifier.wosqualityQ4
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOncology Research and Treatmenten_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleThe Quazar AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of Oral CC-486 in Patients with Acute Myeloid Leukemia (AML) in First Remissionen_US
dc.typeConference Objecten_US
dspace.entity.typePublication

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu